Pneumococcal fusion protein vaccines
AssigneeChildren's Medical Center Corporation
InventorsRichard MALLEY, Yingjie Lu, Fan ZHANG
Life of this patent
Estimating the term…
Abstract
Technologies for the prevention and/or treatment of pneumococcal infections.
Claims16
A method comprising expressing a protein from a heterologous nucleic acid sequence, the heterologous nucleic acid sequence comprising, in any order, a nucleic acid sequence of SEQ ID NO:
- 10 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 10;
- a nucleic acid sequence of SEQ ID NO:
- 14 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 14;
- and a nucleic acid sequence of SEQ ID NO:
- 12 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 12.
A method comprising growing a cell transfected with a heterologous nucleic acid in conditions sufficient for the production of a protein for use in a multi-component immunogenic composition, wherein the heterologous nucleic acid sequence comprises, in any order, a nucleic acid sequence of SEQ ID NO:
- 10 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 10;
- a nucleic acid sequence of SEQ ID NO:
- 14 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 14;
- and a nucleic acid sequence of SEQ ID NO:
- 12 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 12.
A method comprising transfecting a cell with the expression vector of comprising a heterologous nucleic acid and expressing the protein from the expression vector, wherein the heterologous nucleic acid sequence comprises, in any order, a nucleic acid sequence of SEQ ID NO:
- 10 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 10;
- a nucleic acid sequence of SEQ ID NO:
- 14 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 14;
- and a nucleic acid sequence of SEQ ID NO:
- 12 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 12.
A method comprising obtaining a protein expressed from a heterologous nucleic acid and combining the protein with one or more additional components to form a multi-component immunogenic composition, wherein the heterologous nucleic acid sequence comprises, in any order, a nucleic acid sequence of SEQ ID NO:
- 10 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 10;
- a nucleic acid sequence of SEQ ID NO:
- 14 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 14;
- and a nucleic acid sequence of SEQ ID NO:
- 12 or a nucleic acid sequence at least 85% sequence identity to SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.